1. Home
  2. ITCI
  3. ITCI News

Latest Intra-Cellular Therapies Inc. (ITCI) News on February 5, 2025

ITCI

MT Newswires

2 hours ago

UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating

ITCI

MT Newswires

5 days ago

Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119

Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now
ITCI

Insider Monkey

10 days ago

Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now
ITCI

Insider Monkey

12 days ago

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now

Biotech Venture Investors Optimistic, But Uncertainties Persist
ITCI

The Wall Street Journal

13 days ago

Biotech Venture Investors Optimistic, But Uncertainties Persist

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
ITCI

GuruFocus.com

13 days ago

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk
ITCI

Yahoo Finance

14 days ago

Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
ITCI

Yahoo Finance

14 days ago

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

ITCI

MT Newswires

14 days ago

RBC Downgrades Intra-Cellular Therapies to Sector Perform From Outperform on Proposed Sale to Johnson & Johnson

Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally
ITCI

Insider Monkey

17 days ago

Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally

Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’
ITCI

Insider Monkey

18 days ago

Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’

Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
ITCI

Zacks

19 days ago

Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales

J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns
ITCI

GuruFocus.com

21 days ago

J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns

J&J’s Top Rating at Risk Because of Intra-Cellular Deal
ITCI

Bloomberg

21 days ago

J&J’s Top Rating at Risk Because of Intra-Cellular Deal

The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular
ITCI

Zacks

21 days ago

The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular

JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
ITCI

Zacks

22 days ago

JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference

J&J to leverage Intra-Cellular Therapies’ neurology portfolio
ITCI

Pharmaceutical Technology

22 days ago

J&J to leverage Intra-Cellular Therapies’ neurology portfolio

Why Intra-Cellular (ITCI) Led the Monday Upsurge?
ITCI

Insider Monkey

22 days ago

Why Intra-Cellular (ITCI) Led the Monday Upsurge?

ITCI Poised for Turnaround Amid Rising Mental Health Concerns
ITCI

GuruFocus.com

22 days ago

ITCI Poised for Turnaround Amid Rising Mental Health Concerns

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
ITCI

Zacks

22 days ago

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

ITCI

MT Newswires

22 days ago

Piper Sandler Downgrades Intra-Cellular Therapies to Neutral From Overweight, Adjusts Price Target to $132 From $107

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?
ITCI

Zacks

22 days ago

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

ITCI Stock Surges 34% as J&J Reveals $14.6 Billion Acquisition Plan
ITCI

GuruFocus.com

22 days ago

ITCI Stock Surges 34% as J&J Reveals $14.6 Billion Acquisition Plan

JPMorgan Healthcare Conference: AI, billion-dollar deals
ITCI

Yahoo Finance Video

23 days ago

JPMorgan Healthcare Conference: AI, billion-dollar deals

These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More
ITCI

Barrons.com

23 days ago

These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug
ITCI

Investor's Business Daily

23 days ago

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug

Johnson & Johnson Strikes $14.6 Billion Deal to Acquire Intra-Cellular Therapies
ITCI

MT Newswires

23 days ago

Johnson & Johnson Strikes $14.6 Billion Deal to Acquire Intra-Cellular Therapies

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal
ITCI

Investor's Business Daily

23 days ago

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B
ITCI

Investopedia

23 days ago

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B

ITCI

MT Newswires

23 days ago

Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion

Update: Johnson & Johnson acquires Intra-Cellular Therapies
ITCI

Pharmaceutical Technology

23 days ago

Update: Johnson & Johnson acquires Intra-Cellular Therapies

ITCI

MT Newswires

23 days ago

Market Chatter: Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal
ITCI

The Wall Street Journal

23 days ago

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement
ITCI

TipRanks

25 days ago

RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement

ITCI

GuruFocus.com

a month ago

Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz

ITCI

MT Newswires

a month ago

Update: Intra-Cellular Therapies, Sandoz Settle CAPLYTA Patent Litigation

ITCI

MT Newswires

a month ago

Intra-Cellular Therapies, Sandoz Settle CAPLYTA Patent Litigation

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
ITCI

GlobeNewswire

a month ago

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz

ITCI

MT Newswires

a month ago

RBC Trims Price Target on Intra-Cellular Therapies to $108 From $112, Keeps Outperform Rating

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ITCI

GlobeNewswire

a month ago

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Turn A Profit?
ITCI

Simply Wall St.

a month ago

When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Turn A Profit?

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
ITCI

GlobeNewswire

2 months ago

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting

ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
ITCI

Zacks

2 months ago

ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD

ITCI

MT Newswires

2 months ago

Intra-Cellular Therapies Files Supplemental NDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
ITCI

GlobeNewswire

2 months ago

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
ITCI

Zacks

2 months ago

Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?

How Intra-Cellular surprised Wall Street by breaking character
ITCI

BioPharma Dive

2 months ago

How Intra-Cellular surprised Wall Street by breaking character

ITCI

MT Newswires

3 months ago

UBS Raises Price Target on Intra-Cellular Therapies to $87 From $79, Maintains Neutral Rating

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
ITCI

GlobeNewswire

3 months ago

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

ITCI

MT Newswires

3 months ago

Intra-Cellular Therapies Insider Sold Shares Worth $3,692,100, According to a Recent SEC Filing

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
ITCI

GlobeNewswire

3 months ago

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

Intra-Cellular bolsters Caplyta data with another Phase III win
ITCI

Pharmaceutical Technology

3 months ago

Intra-Cellular bolsters Caplyta data with another Phase III win

Intra-Cellular bolsters Caplyta data with another Phase III win
ITCI

Clinical Trials Arena

3 months ago

Intra-Cellular bolsters Caplyta data with another Phase III win

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
ITCI

GlobeNewswire

3 months ago

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results
ITCI

Simply Wall St.

3 months ago

Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results

Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
ITCI

Simply Wall St.

3 months ago

Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

ITCI

GuruFocus.com

3 months ago

Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings Call Highlights: Robust Sales Growth and ...

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
ITCI

Zacks

3 months ago

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
ITCI

Zacks

3 months ago

Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates

ITCI

MT Newswires

3 months ago

Intra-Cellular Therapies Posts Unchanged Q3 Net Loss, Revenue Rises

ITCI

Associated Press Finance

3 months ago

Intra-Cellular: Q3 Earnings Snapshot

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
ITCI

GlobeNewswire

3 months ago

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

What To Expect From Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings
ITCI

GuruFocus.com

3 months ago

What To Expect From Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
ITCI

Zacks

3 months ago

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
ITCI

GlobeNewswire

4 months ago

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds
ITCI

Insider Monkey

4 months ago

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
ITCI

Zacks

4 months ago

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe

ITCI

MT Newswires

4 months ago

Morgan Stanley Raises Price Target on Intra-Cellular Therapies to $95 From $92, Keeps Overweight Rating

JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc
ITCI

GuruFocus.com

4 months ago

JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc

ITCI

MT Newswires

4 months ago

RBC Lifts Price Target on Intra-Cellular Therapies to $108 From $106, Keeps Outperform Rating

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
ITCI

GlobeNewswire

4 months ago

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone
ITCI

Simply Wall St.

5 months ago

Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
ITCI

Zacks

5 months ago

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?

ITCI

MT Newswires

5 months ago

Piper Sandler Upgrades Intra-Cellular Therapies to Overweight From Neutral, $92 Price Target

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now
ITCI

Insider Monkey

5 months ago

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now

ITCI

MT Newswires

5 months ago

Intra-Cellular Therapies Insider Sold Shares Worth $5,089,236, According to a Recent SEC Filing

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
ITCI

GlobeNewswire

5 months ago

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

ITCI

MT Newswires

5 months ago

Intra-Cellular Therapies Insider Sold Shares Worth $9,086,738, According to a Recent SEC Filing

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
ITCI

Simply Wall St.

6 months ago

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon
ITCI

Investor's Business Daily

6 months ago

Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon

ITCI

MT Newswires

6 months ago

UBS Adjusts Price Target on Intra-Cellular Therapies to $79 From $83, Maintains Neutral Rating

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
ITCI

Zacks

6 months ago

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
ITCI

GlobeNewswire

6 months ago

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

ITCI

MT Newswires

6 months ago

RBC Trims Price Target on Intra-Cellular Therapies to $106 From $107, Keeps Outperform Rating

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
ITCI

Investor's Business Daily

6 months ago

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

ITCI

MT Newswires

6 months ago

Intra-Cellular Therapies Appoints Sanjeev Narula CFO

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
ITCI

Zacks

6 months ago

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

ITCI

MT Newswires

6 months ago

Intra-Cellular Therapies Q2 Net Loss Narrows, Revenue Rises

ITCI

Associated Press Finance

6 months ago

Intra-Cellular: Q2 Earnings Snapshot

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
ITCI

GlobeNewswire

6 months ago

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
ITCI

GlobeNewswire

6 months ago

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ITCI

Zacks

6 months ago

Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ITCI

Zacks

6 months ago

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
ITCI

GlobeNewswire

6 months ago

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

ITCI

MT Newswires

6 months ago

Needham Adjusts Intra-Cellular Therapies Price Target to $100 From $94, Maintains Buy Rating

Analysts Expect Breakeven For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Before Long
ITCI

Simply Wall St.

6 months ago

Analysts Expect Breakeven For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Before Long

Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
ITCI

Zacks

7 months ago

Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?

ITCI

MT Newswires

7 months ago

RBC Raises Price Target on Intra-Cellular Therapies to $107 From $103, Keeps Outperform Rating

Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
ITCI

Zacks

7 months ago

Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe

Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
ITCI

Investor's Business Daily

8 months ago

Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87

Share on Social Networks: